Quick Answer
ALNYLAM PHARMACEUTICALS, INC. reported Operating Income Loss of $501.58 million for the year ending 2025.
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +383.6% in Operating Income Loss from 2024 to 2025.
- This data is from ALNYLAM PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), ALNYLAM PHARMACEUTICALS, INC.'s Operating Income Loss has grown by 1,902.0%.
- Historical annual values: Fiscal year 2025: $501.58 million | Fiscal year 2024: -$176.89 million | Fiscal year 2023: -$282.18 million | Fiscal year 2022: -$785.07 million | Fiscal year 2021: -$708.65 million | Fiscal year 2020: -$828.44 million | Fiscal year 2019: -$939.43 million | Fiscal year 2018: -$814.67 million | Fiscal year 2017: -$500.09 million | Fiscal year 2016: -$424.59 million | Fiscal year 2015: -$296.01 million | Fiscal year 2014: -$404.98 million | Fiscal year 2013: -$92.94 million | Fiscal year 2012: -$129.46 million | Fiscal year 2011: -$54.82 million | Fiscal year 2010: -$44.07 million | Fiscal year 2009: -$48.11 million | Fiscal year 2008: -$27.84 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: